Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy induced nausea and vomiting

S. Chiara, P. Scarsi, E. Campora, P. Bruzzi, R. Tatarek, R. Rosso

Research output: Contribution to journalArticle

Abstract

Ninety outpatients with histologically confirmed malignancy receiving chemotherapy entered a randomized cross-over trial to assess the antiemetic efficacy of low-dose metoclopramide versus methylprednisolone. Treatment consisted of either metoclopramide (MCP) 60 mg or methylprednisolone (MPN) 375 mg administered in 3 equal doses just prior to chemotherapy and 6 and 12 hours after treatment. Patients receiving MPN had significantly less nausea (p <0.001) and fewer episodes of vomiting (pp <0.0003) than patients receiving MCP. MPN also proved to be the more effective agent in cross-over trials. Both MPN and MCP were well tolerated. No important side effects were observed. MPN is a safe, effective, antiemetic treatment suitable for use in the outpatient.

Original languageEnglish
Pages (from-to)333-336
Number of pages4
JournalChemioterapia
Volume3
Issue number5
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy induced nausea and vomiting'. Together they form a unique fingerprint.

  • Cite this

    Chiara, S., Scarsi, P., Campora, E., Bruzzi, P., Tatarek, R., & Rosso, R. (1984). Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy induced nausea and vomiting. Chemioterapia, 3(5), 333-336.